Patents by Inventor John A. Hood

John A. Hood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240136552
    Abstract: Disclosed herein are aspects of methods to control airflow to a fuel cell stack and a cooling fan within a housing by fluidly connecting a predetermined minimum volume of airflow through the housing to the fan and a series of louvres, adjustable apertures, and bypass valves dynamically adjust the air flow to at least one of one of the fuel cell stack and fan providing the required minimum volume of fluid to the fan during different controller based modes of operation.
    Type: Application
    Filed: May 19, 2022
    Publication date: April 25, 2024
    Applicant: Intelligent Energy Limited
    Inventors: Tom Peter HOOD, Harry John KARMAZYN, Jesse Thomas Robin Dufton
  • Publication number: 20240116927
    Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Application
    Filed: May 10, 2023
    Publication date: April 11, 2024
    Inventors: John Hood, David Mark Wallace, Sunil Kumar KC
  • Patent number: 11839679
    Abstract: The present disclosure relates to ?-diketone compounds, such as those having the structures: The disclosure also relates to cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for improving the aesthetic appearance of a subject's skin, for example, improving one or more of skin tone, radiance, clarity, tautness, skin firmness, plumpness, suppleness, softness, skin texture, skin texturization and moisturization, appearance of skin contours, appearance of hollow cheeks, appearance of sunken, baggy, or dark circles under eyes, skin luster, brightness, skin thickness, and skin elasticity and/or resiliency comprising application of the compounds or compositions disclosed.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: December 12, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, Sunil Kumar Kc, Osman Kibar, Charlene F. Barroga
  • Patent number: 11780823
    Abstract: Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: October 10, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, Sunil Kumar KC
  • Patent number: 11697649
    Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: July 11, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, David Mark Wallace, Sunil Kumar KC
  • Publication number: 20230201196
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco, Luis A. Dellamary, Sunil K. KC
  • Publication number: 20230201195
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco
  • Patent number: 11684615
    Abstract: This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: June 27, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: Vishal Deshmukh, Eric Anthony Murphy, John Hood
  • Publication number: 20230181584
    Abstract: The present specification provides methods for treating cancers characterized in having an activated hedgehog pathway.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 15, 2023
    Inventors: Miguel de los Rios, John Hood
  • Patent number: 11673885
    Abstract: The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: June 13, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
  • Patent number: 11667632
    Abstract: Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: June 6, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, David Mark Wallace, Sunil Kumar KC, Yusuf Yazici, Christopher Swearingen, Luis A Dellamary
  • Patent number: 11628167
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 18, 2023
    Assignee: Endeavor Biomedicines, Inc.
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco
  • Publication number: 20230053726
    Abstract: The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
    Type: Application
    Filed: April 27, 2021
    Publication date: February 23, 2023
    Inventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
  • Publication number: 20230047396
    Abstract: Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Application
    Filed: June 14, 2021
    Publication date: February 16, 2023
    Inventors: John Hood, Sunil Kumar KC
  • Patent number: 11560378
    Abstract: Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: January 24, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, David Mark Wallace, Sunil Kumar KC, Yusuf Yazici, Christopher Swearingen, Luis A Dellamary
  • Publication number: 20230013144
    Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Application
    Filed: February 5, 2021
    Publication date: January 19, 2023
    Inventors: John Hood, David Mark Wallace, Sunil Kumar KC
  • Publication number: 20230000842
    Abstract: Provided herein are methods of treating cartilage disorders in a subject using a dual CLK/DYRK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, or a combination of a CLK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, and DYRK inhibitor or, pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: January 17, 2020
    Publication date: January 5, 2023
    Inventors: Vishal Deshmukh, Alyssa-Lauren O'Green, Carine Bossard, Charlene F. Barroga, John Hood
  • Publication number: 20220265650
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Application
    Filed: May 3, 2022
    Publication date: August 25, 2022
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco
  • Patent number: 11400092
    Abstract: The present disclosure provides methods of mitigating thiamine deficiency.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: August 2, 2022
    Assignee: Impact Biomedicines, Inc.
    Inventors: Tymara Berry, John Hood, Catriona Jamieson, Curtis L. Scribner
  • Publication number: 20220133724
    Abstract: The present disclosure provides methods of mitigating thiamine deficiency.
    Type: Application
    Filed: December 23, 2021
    Publication date: May 5, 2022
    Inventors: Tymara Berry, John Hood, Catriona Jamieson, Curtis L. Scribner